Drug Trial Radar · NCT06343805
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
256
Planned (sponsor's estimate)
Start
Oct 3, 2024
Primary completion
Jun 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
J8G-MC-JDIA (AJX-101) is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in biomarkers of an orally administered type II Janus Kinase 2 (JAK2) inhibitor, LY5830966, in participants with primary or secondary myelofibrosis previously treated with at least one type I JAK2 inhibitor.
Conditions
- Primary Myelofibrosis
Interventions
LY5830966Drug
Type II JAK2 Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with treatment-emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).Time frame: Baseline through study completion, an average of 1 year
- Number of patients with Dose Limiting Toxicities (DLTs)Time frame: Baseline through study completion, an average of 1 year
- To establish the maximum tolerated dose (MTD) and/or recommended phase 3 dose (RP3D) of LY5830966Time frame: Baseline through study completion, an average of 1 year
Locations
21 sites in 5 countries. Site status is shown where the registry gives one.
Stanford Cancer Institute
Palo Alto, California · Recruiting
Moffitt Cancer Cancer Center
Tampa, Florida · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
David H. Koch Center for Cancer Care at Memorial Sloan Kettering
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
University of Cincinnati
Cincinnati, Ohio · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
AP-HP Hopital Saint-Louis
Paris, France · Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna, Italy, Italy · Not yet recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy, Italy · Not yet recruiting
Hospital Clinic Barcelona
Barcelona, Spain · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
Hospital General Universitario Gregorio Maranon
Madrid, Spain, Spain · Recruiting
Guy's Hospital
London, UK, United Kingdom · Not yet recruiting
Genesis Cancer Care UK Limited - Oxford
Oxford, UK, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.